Investor Brand Network

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at the Beverly Hilton in Los Angeles. According to the announcement, Doug Drysdale, Cybin CEO, will appear on a panel entitled “Collaborating for Improved Mental Health,” on May... (continue reading...)

A recent report by the U.S. Department of Agriculture points to the hemp industry becoming more stable, particularly with regard to price and acreage. This is welcome, especially by players in the industry that have had to grapple with instability since the crop was legalized in 2018.

One statistician at the federal agricultural agency, Joshua Bates, stated in the report that after legalization, hemp experienced a boom followed by a slump. However, now things are... (continue reading...)

Sustain Southern California (“Sustain SoCal”), a non-profit organization accelerating cleantech economic growth and sustainability, is announcing plans to host the Waste Stream Management and Circularity Conference. The in-person event is set to take place at the Frank R. Bowerman Landfill in Irvine, California, on Wednesday, May 15, 2024. In collaboration with Orange County Waste and Recycling, Sustain SoCal will delve into the pressing issues surrounding waste... (continue reading...)

Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, Nutriband’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse... (continue reading...)

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, is reporting positive results from a phase 2A pilot study of PH15, its investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. According to the data, which has not been reported before, PH15 exhibited a... (continue reading...)